Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Lupin had been marketing Huminsulin through an existing agreement with Lilly India before proceeding to acquire the brand. Huminsulin is used in the treatment of Type 1 and Type 2 diabetes mellitus.

Lupin Ltd acquires Huminsulin from Eli Lilly to expand diabetes portfolio, offering a range of human insulin options.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...